Yahoo Finance Medicure Full Year 2023 Earnings: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)
Medicure (CVE:MPH) Full Year 2023 Results
Key Financial Results
Revenue: CA$21.7m (down 5.9% from FY 2022).
Net loss: CA$922.0k (down by 168% from CA$1.37m profit in FY 2022).
CA$0.088 loss per share (down from CA$0.13 profit in FY 2022).
MPH Products In Clinical Trials
Phase III: 1.
MPH Post-Clinical Trial Products
Pre-registration: 1.
Approved (during full year): 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medicure's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Medicure that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
